Hemoglobin levels, β2-microglobulin, serum CXCL13, and galectin-9 were considered excellent for predicting responders and non-responders CLL patients with cut-off values > 10 g/dL, < 3.5 mg/dL, < 120 pg/mL, and < 650 pg/mL, respectively (p = 0.001, p = 0.002, p < 0.0001, and p < 0.0001, respectively). This evidence concerns the gene CXCL13 and B-cell chronic lymphocytic leukemia.